La revue de medecine interne, 2021-03, Vol.42 (3), p.227
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?
- Ist Teil von
- La revue de medecine interne, 2021-03, Vol.42 (3), p.227
- Ort / Verlag
- France
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Sprache
- Französisch
- Identifikatoren
- eISSN: 1768-3122DOI: 10.1016/j.revmed.2021.02.001Titel-ID: cdi_pubmed_primary_33612319
- Format
- –
- Schlagworte
- Adolescent, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic - methods, Clinical Trials as Topic - organization & administration, Clinical Trials as Topic - standards, COVID-19 - epidemiology, COVID-19 - therapy, COVID-19 Vaccines - adverse effects, COVID-19 Vaccines - therapeutic use, Female, Follow-Up Studies, Humans, Immunotherapy, Active - adverse effects, Immunotherapy, Active - methods, Immunotherapy, Active - statistics & numerical data, Male, Middle Aged, Pandemics, Patient Safety - standards, RNA, Messenger - adverse effects, RNA, Messenger - therapeutic use, SARS-CoV-2 - genetics, SARS-CoV-2 - immunology, Treatment Outcome, Young Adult